Arno Therapeutics, Inc. is a biopharmaceutical company, which focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. The company is headquartered in Flemington, New Jersey. The company went IPO on 2008-06-11. The firm's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The firm is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
Follow-Up Questions
What is Arno Therapeutics Inc (ARNI)'s P/E Ratio?
The P/E ratio of Arno Therapeutics Inc is 0
Who is the CEO of Arno Therapeutics Inc?
Dr. Alexander Zukiwski is the Chief Executive Officer of Arno Therapeutics Inc, joining the firm since 2011.
What is the price performance of ARNI stock?
The current price of ARNI is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Arno Therapeutics Inc?
Arno Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
